Staidson (Beijing) BioPharmaceuticals Co., Ltd. (SHE:300204)
China
· Delayed Price · Currency is CNY 16.97
+2.19 (14.82%)
May 23, 2025, 1:45 PM CST
SHE:300204 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Operating Revenue | 293.05 | 324.82 | 364.04 | 548.99 | 584.28 | 425.21 | Upgrade
|
| Other Revenue | - | - | 0.13 | - | 0.01 | - | Upgrade
|
| Revenue | 293.05 | 324.82 | 364.18 | 548.99 | 584.29 | 425.21 | Upgrade
|
| Revenue Growth (YoY) | -25.65% | -10.81% | -33.66% | -6.04% | 37.41% | -35.72% | Upgrade
|
| Cost of Revenue | 60.57 | 62.27 | 74.6 | 101.77 | 116.43 | 77.64 | Upgrade
|
| Gross Profit | 232.48 | 262.54 | 289.57 | 447.22 | 467.86 | 347.57 | Upgrade
|
| Selling, General & Admin | 180.54 | 195.91 | 248.23 | 310.77 | 336.76 | 287.94 | Upgrade
|
| Research & Development | 92.82 | 107.11 | 412.26 | 362.81 | 362.51 | 243.68 | Upgrade
|
| Other Operating Expenses | -6.01 | -6.33 | 4.21 | 6.72 | 7.82 | 6.23 | Upgrade
|
| Operating Expenses | 267.36 | 296.68 | 663.22 | 681.08 | 707.37 | 537.39 | Upgrade
|
| Operating Income | -34.89 | -34.14 | -373.64 | -233.87 | -239.51 | -189.82 | Upgrade
|
| Interest Expense | - | - | -1.17 | -0.36 | -0.65 | -1.02 | Upgrade
|
| Interest & Investment Income | 0.14 | 0.14 | 2.65 | 7.32 | 22.19 | 20.2 | Upgrade
|
| Currency Exchange Gain (Loss) | - | - | 0 | 0 | -0 | 0.13 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.51 | -0.6 | 0.02 | -0.24 | 1.46 | -4.87 | Upgrade
|
| EBT Excluding Unusual Items | -35.24 | -34.6 | -372.14 | -227.14 | -216.51 | -175.38 | Upgrade
|
| Impairment of Goodwill | - | - | - | -2.42 | - | - | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | -0 | -1.46 | 0.21 | -1.76 | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.28 | 0.28 | 0.3 | -0.04 | - | 2.23 | Upgrade
|
| Asset Writedown | 0 | 0 | -2.34 | -21.71 | -0.09 | -0.2 | Upgrade
|
| Other Unusual Items | - | - | 7.74 | 9.69 | 3.42 | 14.96 | Upgrade
|
| Pretax Income | -34.95 | -34.32 | -366.45 | -243.07 | -212.96 | -160.15 | Upgrade
|
| Income Tax Expense | 113.42 | 113.42 | 32.44 | -46.06 | -75.56 | -27.13 | Upgrade
|
| Earnings From Continuing Operations | -148.37 | -147.73 | -398.89 | -197.01 | -137.4 | -133.02 | Upgrade
|
| Minority Interest in Earnings | 4.96 | 2.89 | - | - | - | - | Upgrade
|
| Net Income | -143.41 | -144.84 | -398.89 | -197.01 | -137.4 | -133.02 | Upgrade
|
| Net Income to Common | -143.41 | -144.84 | -398.89 | -197.01 | -137.4 | -133.02 | Upgrade
|
| Shares Outstanding (Basic) | - | 483 | 475 | 481 | 474 | 475 | Upgrade
|
| Shares Outstanding (Diluted) | - | 483 | 475 | 481 | 474 | 475 | Upgrade
|
| Shares Change (YoY) | - | 1.67% | -1.17% | 1.42% | -0.27% | 4.41% | Upgrade
|
| EPS (Basic) | - | -0.30 | -0.84 | -0.41 | -0.29 | -0.28 | Upgrade
|
| EPS (Diluted) | - | -0.30 | -0.84 | -0.41 | -0.29 | -0.28 | Upgrade
|
| Free Cash Flow | -82.64 | -87.21 | -260.47 | -232.12 | -218.31 | -163.46 | Upgrade
|
| Free Cash Flow Per Share | - | -0.18 | -0.55 | -0.48 | -0.46 | -0.34 | Upgrade
|
| Gross Margin | 79.33% | 80.83% | 79.52% | 81.46% | 80.07% | 81.74% | Upgrade
|
| Operating Margin | -11.90% | -10.51% | -102.60% | -42.60% | -40.99% | -44.64% | Upgrade
|
| Profit Margin | -48.94% | -44.59% | -109.53% | -35.89% | -23.52% | -31.28% | Upgrade
|
| Free Cash Flow Margin | -28.20% | -26.85% | -71.52% | -42.28% | -37.36% | -38.44% | Upgrade
|
| EBITDA | -14.21 | -11.41 | -342.68 | -202.38 | -205.42 | -154.94 | Upgrade
|
| EBITDA Margin | -4.85% | -3.51% | -94.10% | -36.86% | -35.16% | -36.44% | Upgrade
|
| D&A For EBITDA | 20.67 | 22.73 | 30.97 | 31.48 | 34.09 | 34.87 | Upgrade
|
| EBIT | -34.89 | -34.14 | -373.64 | -233.87 | -239.51 | -189.82 | Upgrade
|
| EBIT Margin | -11.90% | -10.51% | -102.60% | -42.60% | -40.99% | -44.64% | Upgrade
|
| Revenue as Reported | - | - | 364.18 | 548.99 | 584.29 | 425.21 | Upgrade
|
Updated Oct 24, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.